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Abstract 
Novel medicated straws were developed based on drug-loaded 
electrospun fibers prepared by direct current electrospinning 
(DCES) and high-speed electrospinning (HSES) of scaled-up 
productivity. Good quality micro- and nanofibers were 
electrospun using both techniques despite the multiple times 
higher throughput rate of HSES based on the scanning electron 
microscopic imaging (SEM). Solid state analyses revealed that 
the poorly soluble model drug carvedilol (CAR) was dispersed 
in an amorphous form in the electrospun polyvinylpyrrolidone 
(PVPK30) fibers. In vitro dissolution studies revealed ultrafast 
drug release from the prepared fibrous formulations inserted into 
plastic straws. Based on the results the developed drug delivery 
system is suitable for storing the formulation in a solid dosage 
form and in situ turning it into liquid form when administered.
Keywords 
high speed electrospinning, amorphous solid dispersions, 
medicated straws, novel drug delivery system
1 Introduction
Due to the increasing number of poorly water-soluble 
drugs in the field of pharmaceutical industry, the urge for the 
development of novel methods aiming the enhanced dissolution 
of these substances is growing [1–3]. Among the various 
techniques the preparation of amorphous solid dispersions 
(ASDs), which are solid state formulations containing a drug 
dispersed in an amorphous form in a carrier (mostly a polymer), 
are proven to be an excellent way of enhancing the dissolution 
properties, thus, advancing bioavailability [4, 5]. Oral solid 
dosage forms also have significant advantages over liquid 
dosage forms, for instance increased stability of the active 
pharmaceutical ingredient (API) and higher dose precision, 
therefore EMA (European Medicines Agency) recommends the 
development of solid dosage forms over liquid formulations [6].
For the preparation of ASDs electrospinning (ES) is one 
of the most appealing methods combining the advantages of 
amorphous drug formulations and huge surface area of the 
fibers, therefore greatly improving dissolution properties. The 
main challenge of ES is the scale-up of the productivity to 
industrial scale [7, 8], for which HSES seems to be the most 
promising solution so far in the pharmaceutical arena [9]. 
HSES combines the drawing force of the electrostatic field and 
the high frequency rotation of the spinneret with sharp edges 
enabling multiple orders of magnitude higher productivity 
while maintaining the fibrous morphology.
Solid dispersion products are marketed mainly in tablet form 
due to its proper patient compliance and easy administration [10]. 
However, there are many cases in which the administration of 
tablets is not the most suitable medication. Dysphagia has been 
reported as a main reason of challenging the administration of 
APIs in tablet form. For instance, dysphagia occurs at different 
stages of Parkinson’s disease [11], Huntington’s disease and 
there are other conditions causing swallowing difficulties 
like muscle weakness [12, 13]. With aging there could also 
appear changes in the swallowing ability [14]. Nevertheless 
the application of tablets can be even more challenging for 
pediatric use since children need different dosing and their 
compliance is usually worse than adults’ [15].
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In order to overcome the described challenges other ways 
making the administration easier also have to be considered 
such as the application of orally disintegrating tablets, oral thin 
film technology [16] and medicated straws. In these cases the 
storage of the active agent is implemented in solid state. Patient 
compliance can be further improved if undesired sticking of the 
dosage form on the oral mucosa can be avoided and adequate 
taste masking is also achievable which is especially important 
in the case of children. Medicated straws have the potential to 
fulfil these requirements. However, only a few medicated straws 
have been reported so far which contained pellets and granules 
as primary formulation and neither of those studies provided 
details about the in vitro dissolution of the drug [15, 17, 18].
In this study the first attempt is described of combining the 
medicated straw technique and ASD formulations based on 
fibers with ultrafast drug release. The model drug CAR is a 
widely applied antihypertensive BCS II drug usually applied in 
a poorly water-soluble crystalline form in the distributed tablets 
in the doses of 6.25 mg, 12.5 mg and 25 mg [19]. Due to its weak 
basic nature its solubility can be enhanced by complexation 
with cyclodextrins [20], however, the preparation of CAR-
loaded amorphous solid dispersions has served even better 
results [21, 22]. For the dose of CAR 6.25 mg was chosen. 
Conventional DCES and scaled-up HSES were used to prepare 
CAR-loaded fibers [9]. For the matrix the popular polymer 
carrier in ASDs, PVP was chosen [10, 23], however applied 
solely it is a poor complexing agent [24]. Besides constructing 
the straws with electrospun fibers, solid state analyses were 
applied to explore the physical state of the drug in the solid 
dispersions and in vitro dissolution studies were carried out on 
the newly developed drug delivery system.
2 Materials and methods
2.1 Materials
Polyvinylpyrrolidone K30 (PVPK30, 50.000 Da) was 
purchased from BASF. Carvedilol (CAR) from Sigma-Aldrich 
(Budapest, Hungary) was used as API. Absolute methanol 
(MeOH) was purchased from Molar Chemicals (Budapest, 
Hungary). For the development of medicated straws commercial 
plastic straws were purchased.
2.2 Direct current electrospinning (DCES)
The DCES tests were conducted using an NT-35 high 
voltage direct current supply (MA2000; Unitronik Ltd, 
Nagykanizsa, Hungary). The electrical potential applied on 
the spinneret electrode was 25 kV. A grounded aluminum plate 
covered with aluminum foil was used as collector. The distance 
of the spinneret and the collector was 20 cm. Solutions of the 
polymeric excipient and the drug were prepared for ES using a 
magnetic stirrer (600 rpm). The solutions were dosed by a SEP-
10S Plus type syringe pump through a needle spinneret (1 mm 
ID, 2 mm OD) at 5 mL/h rate.
2.3 High speed electrospinning (HSES)
The HSES experiments were performed by using a SEP-
10S Plus type syringe pump similarly to the case of the DCES 
experiments. The solutions were dosed at 1500 mL/h to the HSES 
device (Quick 2000, Tiszavasvári, Hungary) with a rotating 
spinneret (40.000 rpm). The applied electrical potential was 60 
kV. The distance of the spinneret and the collector was 35 cm.
2.4 Scanning electron microscopy (SEM)
Morphology of the samples was investigated by a JEOL 
6380LVa (JEOL, Tokyo, Japan) type scanning electron 
microscope. Each specimen was fixed by conductive double-
sided carbon adhesive tape and sputter-coated with gold prior 
to the examination. Applied accelerating voltage and working 
distance were 20 kV and 10 mm, respectively.
2.5 Differential scanning calorimetry (DSC)
Differential scanning calorimetry measurements were 
carried out using a Setaram (Calure, France) DSC 92 apparatus 
(sample weight: ~10-15 mg, open aluminum pan, nitrogen 
flush). The temperature program consisted of an isothermal 
period, which lasted for 1 min at 25 °C, with subsequent linear 
heating from 25 °C to 220 °C at the rate of 10 °C/min. Purified 
indium standard was used to calibrate the instrument.
2.6 X-ray powder diffraction (XRPD)
X-ray powder diffraction patterns were recorded by a 
PANanalytical X′pert Pro MDP X-ray diffractometer (Almelo, 
The Netherlands) using Cu-Kα radiation (1.542 Å) and Ni 
filter. The applied voltage was 40 kV while the current was 30 
mA. The untreated materials and the fibrous samples as spun 
were analyzed for angles 2θ between 4° and 42°.
2.7 Raman microspectroscopy
Raman spectroscopy measurements were carried out using 
a Horiba Jobin–Yvon LabRAM (Longjumeau, France) system 
coupled with an external diode laser source (785 nm, 80 mW) 
and an Olympus BX-40 optical microscope. The fibrous 
samples were gently compressed into a flat tablet (Camilla 
OL95; Manfredi, Torino, Italy) and the spectra were recorded 
with an objective of 10× magnification.
2.8 In vitro dissolution tests
The dissolution studies were performed using a Harward 
Apparatus 33 type syringe pump (Artisan Technology Group, 
Champaign, USA). Each straw containing 62.5 mg fibers 
equivalent to 6.25 mg CAR dose was vertically fixed in a 
lab stand and 100 mL of distilled water was fed through in 
20 mL portions at 6 mL/s (21.6 L/h) dosing rate from bottom 
to top modeling the sipping of a person with a straw. The 
solution fractions were collected in 20 mL volumetric flasks 
containing 168 µL 37 w/w% HCl solution in order to set the 
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pH of the solutions to the gastric pH. An Agilent 8453 UV–Vis 
spectrophotometer (Palo Alto, California) was used to measure 
the concentration of the dissolved CAR at a wavelength of 242 
nm. Percentage of dissolution was readily calculated according 
to the calibration curve of CAR due to the lack of absorption 
peaks of the applied excipients in this range.
3 Results and Discussion
3.1 Optimization of ES and preparing drug-loaded 
PVPK30 fibers
Firstly, the concentration of PVPK30 in MeOH had to be 
optimized for ES in order to prepare good quality electrospun 
fibers preferably free from beads and droplets. Previous 
studies with PVPK30 have reported the production of defect-
free, good quality nanofibers from PVPK30/EtOH solutions 
[25, 26], however, when MeOH was applied instead of EtOH 
during the DCES process, 2.7 g PVPK30 in 10 mL MeOH was 
required to produce fibers suitable for further experiments. 
At a dosing rate of 5 mL/h smooth operation of ES could 
be achieved without drying or spattering of the liquid jet. 
Based on the optimized composition HSES was also tested 
with scaled-up productivity. The same solution could be 
electrospun with HSES at an increased 1500 mL/h providing 
a dry fibrous fabric in good agreement with previous studies 
reporting no need of change in solution properties to conduct 
HSES [9]. As it can be seen in Fig. 1 the incorporation of the 
drug into the matrix at 10% weight ratio did not deteriorate 
fiber morphology, however, the average diameter of the 
HSES fibers was one order of magnitude larger than that of 
the DCES nanofibers. The SEM images of the HSES product 
show fibers with diameters ranging ~1 µm-10 µm while DCES 
mat comprises of ~90 nm-400 nm nanofibers. Moreover, there 
are slightly more beads on the HSES fibers. The observed 
differences can be attributed to the 300 times higher feeding 
rate and the more intense forces of HSES exerted on the 
polymeric liquid compared to the laboratory scale DCES [9].
3.2 Solid state analyses with DSC, XRPD and Raman 
spectroscopy
The physical state of the drug in the fibers was firstly 
investigated with DSC. The melting point of the pure 
crystalline CAR at 117 °C is clearly detectable as a sharp peak 
(Fig. 2). In the case of PVPK30 only the wide peak of water 
loss can be observed below 100 °C, i.e., the matrix is fully 
amorphous. The drug-loaded DCES and HSES samples show 
no sign of crystalline traces at 117 °C, thus, according to the 
DSC measurements CAR turned into amorphous with both 
DCES and HSES.
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Fig. 2 DSC thermogram of the crystalline CAR, PVPK30 and the drug-loaded 
electrospun fibers.
Additional analysis was carried out with XRPD as an 
effective method to investigate the crystallinity of drug-loaded 
formulations [27]. The results of the XRPD measurements can 
be seen in Fig. 3. Sharp diffraction peaks of crystalline CAR are 
also easily identified, the most intense peaks are at around 2θ= 
6° and 17°. PVPK30 was found to be amorphous as well as the 
formulated drug-loaded electrospun fibers in good accordance 
with the results of the DSC measurements.
Fig. 1 a) SEM images of drug-loaded DCES fibers; b) SEM images of drug-loaded HSES fibers.
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Fig. 3 X-ray powder diffraction of crystalline CAR, PVPK30 and the 
drug-loaded electrospun fibers.
Another sensitive method - Raman spectroscopy - was 
used to verify the presumably molecularly dispersed state of 
the drug in the electrospun fibers since the Raman peaks of 
amorphous and crystalline carvedilol distinctly differ allowing 
the identification of the presence of small crystalline particles 
in the formulation [28, 29]. The Raman spectra of the examined 
materials are shown in Fig. 4. The spectrum of crystalline CAR 
shows sharp peaks among which the most intensive - the C-C 
and C-N symmetric stretchings - are centered around 1290 cm-1 
[30]. PVPK30 rather has broad characteristic peaks referring 
to its amorphous state and also has a sharp peak at around 930 
cm-1 reported to display the ring breathing of the pyrrolidone 
function [31]. The characteristic peaks of CAR is detectable in 
both DCES and HSES fibers, however, in a more broaden and 
less intense form signifying the transformation of CAR from 
crystalline to a fully amorphous form.
3.3 Development of novel electrospun web-loaded 
medicated straws
Micro and nanofibers of 62.5 mg with the composition 
of PVPK30+10%CAR were loaded into transparent plastic 
straws with an inner diameter of 6 mm using a clip (Fig. 5 a). 
To avoid the slipping of the fibers out of the straw during the 
administration by the patients barriers made of plastic tubes 
(5 mm long, Fig. 5 b, c) were placed before the fibers 40 mm 
from the upper end of the straws. This way the tubes closed 
up together and pressed up against the plastic wall, thus, 
mechanically fixing their position without the need for any 
other additives (e.g., glue).
Instead of using a clip to manually load the fibers a possible 
quicker way could be sucking the fibers into the straws with 
vacuum. However, in this case care must be taken since the 
more wrinkled fibrous web can lead to slower dissolution 
of the product due to the higher pressure drop on the straw. 
Therefore, the intensification of the production process 
requires further developments.
3.4 In vitro dissolution tests
In vitro testing the dissolution of the electrospun web-
loaded medicated straws necessitated the determination of 
the throughput of human sipping. A group of 15 adults (6 
females, 9 males) was examined to sip tap water from a glass 
for 5 seconds with the same straws used for our experiments. 
The sipping processes was conducted with each subject in 
triplicate. The average sipping speed was calculated after 
weighing of the remaining water. The grand average sipping 
speed of the participants was determined to be 6.0±1.3 mL/s. 
The dissolution tests were executed by feeding the water at the 
obtained dosing rate, 5 sips of 20 mL solutions were sampled 
which equals to an average sip with a straw for adults [32].
Fig. 4 Raman shifts of crystalline CAR, PVPK30 and the drug-loaded electrospun fibers.
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Fig. 5 a) Developed medicated straw with drug-loaded fibers; 
b) Plastic tubes in a straw; c) Plastic tubes in detail.
The results of the dissolution tests are shown in Fig. 6. Both 
DCES and HSES fibers exhibited ultrafast drug dissolution 
since the drug release in the first 20 mL samples was close 
to 80% and exceeded 95% in cases of straws with DCES and 
HSES fibers, respectively. The drug release was practically 
complete within the first two sips with both types of electrospun 
formulation due to the huge surface areas and the amorphously 
dispersed drug in the fibers. The better drug release profile of the 
HSES mat compared to DCES fibers could make one wonder 
since the scaled-up technique produced fibers with significantly 
larger diameters and more beads as shown in Fig. 1. This 
phenomenon can be explained by the better accessibility of 
the loosely collected HSES fibers leading to faster drug release 
despite the thicker average diameter. A similar conclusion has 
been drawn when the drug release from fine yet tightly packed 
DCES fibers and loose melt-blown fibers with one order of 
magnitude larger fiber diameter was compared [33].
4 Conclusions
Micro- and nanofibers loaded with a poorly soluble API were 
prepared for the development of a medicated straw formulation 
using laboratory scale DCES and scaled-up HSES at an 
increased throughput rate of 1500 mL/h. Various solid state 
analyses (DSC, XRPD and Raman microspectroscopy) revealed 
no crystalline traces of CAR in the fibrous fabrics prepared 
with both techniques. A medicated straw was developed for the 
first time based on electrospun fibers by which the formulation 
could be stored in solid state maintaining stability and precise 
dosing and the administration of the drug can be implemented in 
liquid state providing better compliance. The in vitro dissolution 
tests were conducted at a sipping speed of 6 mL/s based on 
measured sipping speeds of a 15-member group. The HSES 
product showed slightly better dissolution compared to DCES 
fibers making the developed drug delivery system feasible for 
advancing patient compliance of geriatric and pediatric uses.
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